Dupilumab efficacy and safety in patients with moderate to severe asthma: A systematic review and meta-analysis

• Main Authors: Mohamed Sayed Zaazouee (Author), Asmaa Gomaa Alwarraqi (Author), Yasmine Adel Mohammed (Author), Mohamed A. Badheeb (Author), Abdullah Mohamed Farhat (Author), Mohammed Eleyan (Author), Afnan Morad (Author), Marwa Abdel-Aziz Zeid (Author), Aya Shaban Mohamed (Author), Hazem AbuEl-Enien (Author), Ahmed Abdelalim (Author), Ahmed Bostamy Elsnhory (Author), Yasmin S. M. Hrizat (Author), Nagat Taha Altahir (Author), Doaa Atef (Author), Alaa Ahmed Elshanbary (Author), Khalaf F. Alsharif (Author), Khalid J. Alzahrani (Author), Mohammad Algahtani (Author), Abdulrahman Theyab (Author), Yousef M. Hawsawi (Author), Ahmed A. Aldarmahi (Author), Mohamed M. Abdel-Daim (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Dupilumab is a human monoclonal antibody directed against the alpha subunit of the interleukin-4 receptor and inhibits the signaling of IL-4 and IL-13. It is approved for treating asthma and other type-2 inflammatory diseases. There is a conflict in the literature regarding the safety an...